Synergia Medical is marking two years of first-in-human experience with NAO·VNS™, its investigational optoelectronic vagus nerve stimulation system for drug-resistant epilepsy, in the AURORA study at UZ Gent and Cliniques universitaires Saint-Luc (UCLouvain). The five-patient feasibility study met its primary safety endpoint at three months, with reliable stimulation delivery, and longer follow-up shows encouraging outcomes, including improved quality of life; a final report and scientific publication will establish their magnitude and durability. NAO·VNS™ uses light inside the implant to power and control electrical stimulation of the vagus nerve. The company is now raising a new financing round to fund the next clinical stage and a stronger US strategy, and US medical-device executive Paul Hanchin will become CEO once the round closes.
Synergia Medical marks two years of first-in-human experience with NAO·VNS™ in the AURORA study
